BioCentury
BioCentury
ARTICLE | Deals

BMS sees potential first-in-class therapy in deal for Agenus’ bispecific TIGIT-targeting mAb

By Paul Bonanos, Associate Editor
May 18, 2021 11:36 AM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

Agenus Inc.

Bristol Myers Squibb Co.

BCIQ Target Profiles

T cell immunoreceptor with Ig and ITIM domains (TIGIT)

BCIQ Company Profiles

Agenus Inc.

Bristol Myers Squibb Co.

BCIQ Target Profiles

T cell immunoreceptor with Ig and ITIM domains (TIGIT)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS